| Trial ID: | L4260 |
| Source ID: | NCT00653341
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin glargine|DRUG: NPH human insulin
|
| Outcome Measures: |
Primary: Percentage of subjects reaching target HbA1c = or < 7% at endpoint and not experiencing symptomatic nocturnal hypoglycemia | Secondary: Safety data (Adverse events, vital signs, laboratory values, etc.)
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
764
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-01
|
| Completion Date: |
2001-10
|
| Results First Posted: |
|
| Last Update Posted: |
2009-04-20
|
| Locations: |
Sanofi-aventis administrative office, Bridgewater, New Jersey, 08807, United States|Sanofi-aventis administrative office, Laval, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00653341
|
